Chante Smith-Fason, APRN
Family · Memphis, TNNPI 1902966765
Payments from drug & device makers
Across 650 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Supernus Pharmaceuticals, Inc.$836
- Neurocrine Biosciences, Inc.$833
- plus $5K from 21 others
What the payments were for
- Food & beverage$13,38199%
- Education$1211%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 163 | $2,839 |
| Alkermes, Inc. | 58 | $1,714 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 56 | $1,356 |
| Otsuka America Pharmaceutical, Inc. | 76 | $1,275 |
| Supernus Pharmaceuticals, Inc. | 24 | $836 |
| Neurocrine Biosciences, Inc. | 38 | $833 |
| Johnson & Johnson | 36 | $724 |
| Vanda Pharmaceuticals Inc. | 35 | $688 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $471 |
| Lundbeck LLC | 19 | $350 |
| Axsome Therapeutics, Inc. | 13 | $267 |
| Tris Pharma Inc | 13 | $230 |
| Teva Pharmaceuticals USA, Inc. | 10 | $228 |
| Bausch Health US, LLC | 10 | $213 |
| Merck | 13 | $210 |
| Corium, LLC | 8 | $208 |
| E.r. Squibb & Sons, L.L.C. | 4 | $175 |
| Idorsia Pharmaceuticals US Inc | 9 | $173 |
| Indivior Inc. | 8 | $139 |
| Sunovion Pharmaceuticals Inc. | 7 | $138 |
| Ironshore Pharmaceuticals Inc. | 8 | $123 |
| AstraZeneca | 1 | $122 |
| Acadia Pharmaceuticals Inc | 5 | $99 |
| Collegium Pharmaceutical, Inc. | 2 | $34 |
| Noven Therapeutics, LLC | 2 | $24 |
| Adlon Therapeutics L.p. | 1 | $22 |
| Alfasigma USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,502 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 122 | $212,626 |
| IngrezzaValbenazine Tosylate | 22 | $181,739 |
| Abilify MaintenaAripiprazole | 28 | $76,567 |
| Invega SustennaPaliperidone Palmitate | 23 | $53,215 |
| RexultiBrexpiprazole | 20 | $39,576 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $20,763 |
| XanaxAlprazolam | 13 | $15,742 |
| Lurasidone Hcl | 43 | $7,742 |
| VyvanseLisdexamfetamine Dimesylate | 20 | $7,214 |
| Lisdexamfetamine Dimesylate | 15 | $3,976 |
| Ziprasidone Hcl | 40 | $3,782 |
| Aripiprazole | 97 | $3,496 |
| Oxcarbazepine | 60 | $3,103 |
| Paliperidone ErPaliperidone | 13 | $2,890 |
| Vilazodone Hcl | 22 | $2,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,356 | $212,626122 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $833 | $181,73922 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,275 | $116,14248 claims |
| Johnson & JohnsonInvega Sustenna | $724 | $53,21523 claims |
| Alkermes, Inc.Lybalvi | $1,714 | $20,76313 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $471 | $7,21420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Memphis
- Marye BernardMemphis$128K
- Brett SnodgrassMemphis$47K
- John ScallionsMemphis$30K
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.